TNSN98221A1 - Nouvelle forme cristalline d'omeprazole - Google Patents

Nouvelle forme cristalline d'omeprazole

Info

Publication number
TNSN98221A1
TNSN98221A1 TNTNSN98221A TNSN98221A TNSN98221A1 TN SN98221 A1 TNSN98221 A1 TN SN98221A1 TN TNSN98221 A TNTNSN98221 A TN TNSN98221A TN SN98221 A TNSN98221 A TN SN98221A TN SN98221 A1 TNSN98221 A1 TN SN98221A1
Authority
TN
Tunisia
Prior art keywords
methoxy
crystalline form
new crystalline
omeprazole
dimethyle
Prior art date
Application number
TNTNSN98221A
Other languages
English (en)
Inventor
David Noreland
Gunnel Sunden
Ingvar Ymen
Karin Lovqvist
Original Assignee
Astra Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/SE1998/002028 external-priority patent/WO1999008500A2/fr
Application filed by Astra Ab filed Critical Astra Ab
Publication of TNSN98221A1 publication Critical patent/TNSN98221A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

LA PRESENTE INVENTION PORTE SUR UNE NOUVELLE FORME CRISTALLINE DE 5-METHOXY-2-[[4-METHOXY-3,5-DIMETHYLE-2- PYRIDINYLE) METHYLE] SULFINYLE] 1H-BENZIMIDAZOLE, CONNU SOUS LE NOM GENERIQUE D'OMEPRAZOLE. DE PLUS, LA PRESENTE INVENTION PORTE EGALEMENT SUR L'UTILISATION DE LA NOUVELLE FORME CRISTALLINE DE 5-METHOXY-2-[[4-METHOXY - 3,5 - DIMETHYLE -2- PYRIDINYLE]METHYLE)SULFINYLE] 1H-BENZIMIDAZOLE POUR LE TRAITEMENT DE MALADIES GASTROINTESTINALES, SUR LES COMPOSITIONS PHARMACEUTIQUES LE CONTENANT AINSI QUE LES PROCEDES POUR LA PREPARATION DE LA NOUVELLE FORME CRISTALLINE DE 5-METHOXY-2-[[4-METHOXY-3 ,5-DIMETHYLE-2-PYRIDINYLE) METHYLE] SULFINYLE) 1H-BENZIMIDAZOLE.
TNTNSN98221A 1998-11-10 1998-12-08 Nouvelle forme cristalline d'omeprazole TNSN98221A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/SE1998/002028 WO1999008500A2 (fr) 1998-11-10 1998-11-10 Nouvelle forme cristalline d'omeprazole

Publications (1)

Publication Number Publication Date
TNSN98221A1 true TNSN98221A1 (fr) 2005-03-15

Family

ID=43735642

Family Applications (1)

Application Number Title Priority Date Filing Date
TNTNSN98221A TNSN98221A1 (fr) 1998-11-10 1998-12-08 Nouvelle forme cristalline d'omeprazole

Country Status (5)

Country Link
KR (1) KR100572297B1 (fr)
AR (1) AR016700A1 (fr)
MY (1) MY118724A (fr)
SA (1) SA99190998B1 (fr)
TN (1) TNSN98221A1 (fr)

Also Published As

Publication number Publication date
KR20010107953A (ko) 2001-12-07
KR100572297B1 (ko) 2006-04-24
AR016700A1 (es) 2001-07-25
MY118724A (en) 2005-01-31
SA99190998B1 (ar) 2006-03-25

Similar Documents

Publication Publication Date Title
TNSN00017A1 (fr) Sel de potassium d'omeprazole - (s)
MY127871A (en) Omeprazole sodium salt
CA2290963A1 (fr) Trihydrate de magnesium s-omeprazole
TR200101282T2 (tr) Omeprozolün yeni kristalli formu
IL93263A0 (en) Antimicrobial pharmaceutical compositions containing a benzimidazole derivative
CA2274076A1 (fr) Nouvelle forme de compose
ATE269846T1 (de) N-substituierte aminotetraline als neuropeptid y y5 rezeptor-liganden und ihre anwendung zur behandlung von fettleibigkeit und anderen erkrankungen
CA2193994A1 (fr) Procede de synthese de sulfoxydes substitues
TNSN00231A1 (fr) Forme cristalline de 4-carboxyamino-2-substitue-1,2,3,4- tetrahydroquinoleine, et compositions la contenant
TNSN99007A1 (fr) Composition de mesylate de trovafloxacine et procede pour sa preparation
TR199901643T1 (xx) Yeni y�ntem.
TNSN01175A1 (fr) Derives de piperidines antagonistes selectives de sous- types de recepteurs de nmda, et compositions les contenant.
NO981856D0 (no) Anvendelse av 1-(2-naft-2-yletyl)-4-(3-trifluormetylfenyl)-1,2,3,6-tetrahydropyridin for fremstilling av legemidler for behandling av amyotrof lateral sclerose
TNSN98221A1 (fr) Nouvelle forme cristalline d'omeprazole
TNSN00105A1 (fr) Derives de 1-trifluoromethyl-4-hydroxy-7-piperidinyl- aminomethylchromane, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN00095A1 (fr) Benzolactames et thioamides cycliques substitues nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
MA23429A1 (fr) Novelle forme galenique de derives de 5-nitro imidazole efficace pour le traitement des parasitoses et des infections de l'ensemble du tractus-gastro-intestinal.
YU32301A (sh) Novi kristalni oblik omeprazola
TNSN98033A1 (fr) Derives de quinoxalinedione, procede pour leur preparation et compositions pharmaceutiques les contenant.
TNSN96156A1 (fr) Formes zwitterioniques de trovafloxacine, procede pour leur preparation et compositions les contenant
NO974687D0 (no) Kondenserte <beta>-carboliner
TH57762B (th) เกลือโพแทสเซียมของ (s)-โอมีพราโซล